来自日本的研究团队针对新生血管性年龄相关性黄斑变性(nAMD)患者开展了一项回顾性观察研究，比较玻璃体注射aflibercept(2 mg/0.05 mL)与faricimab(6 mg/0.05 mL)对眼压(IOP)的短期影响。结果显示，aflibercept组3个月后IOP显著降低(14.4±2.8 mmHg→13.2±3.0 mmHg，P<0.001)，而faricimab组 ...

The investigators retrospectively evaluated 126 consecutive treatment-naïve nAMD patients (126 eyes) who received a loading ...

Investing.com — UNITY Biotechnology, Inc. [NASDAQ: UBX]，一家市值约3100万美元的小型生物技术公司，今天宣布其UBX1325 Phase 2b ASPIRE临床试验取得积极的初步结果。UBX1325是一种用于治疗糖尿病黄斑水肿(DME)的候选药物。该试验将UBX1325与标准抗VEGF疗法aflibercept进行了比较，发现UBX1325在 ...

Investing.com — 周二，美银美林证券重申了对Unity Biotechnology Inc (NASDAQ: UBX )的"优于大市"评级，目标价维持在6.00美元，此评级是在该公司发布临床试验结果后作出的。该股目前交易价格为1.30美元，过去一周下跌了显著的25%，尽管 InvestingPro 分析表明，该公司在当前水平被低估。Unity ...

Unity Biotechnology’s investigational eye treatment failed to match Eylea at 20 weeks—part of the mid-stage trial’s primary ...

Complete 36-week results from the ASPIRE study involving 52 patients are expected in the second quarter of 2025.

The entire 36-week data for the remaining subjects in the trial is anticipated in the second quarter of this year.

The Australian biotech could potentially be on the hook for more than $1bn after its Wet AMD therapy failed to show impact ...

Opthea (ASX:OPT) has announced that its lead drug candidate sozinibercept has failed to meet primary endpoints in a phase 3 ...

Opthea's Phase 3 COAST trial for wet AMD did not meet its primary endpoint, raising financial concerns as the company faces ...

The phase 3 COAST trial investigating 2 mg sozinibercept for the treatment of wet age-related macular degeneration in ...

Treatment with UBX1325 resulted in vision gains comparable to aflibercept at weeks 24 and 36 in difficult-to-treat patient populationUBX1325 was ...